彭鑫，助理教授、博士生导师、研究员。2015年获得天津医科大学学士学位，2020年获得天津医科大学博士学位（2019年至2020年，先后作为MD安德森癌症中心系统生物学系及生物信息学系联培博士）。获得天津市自然科学二等奖，天津市“海河英才”创新创业大赛博士后揭榜领题赛铜奖。入选中国科协“青年人才托举工程”项目。主持6项国家级及省部级科研课题。 老虎机游戏引进人才，2024年加入老虎机游戏。曾于2021年至2024年在天津医科大学任博士后；2020年至2021年在MD安德森癌症中心任博士后。

长期从事以基于多组学数据挖掘结合实验筛选平台，进行肿瘤新药研发与精准治疗研究。涉及抗肿瘤药物靶点发现及合成、DNA损伤疗法增敏生物标志物筛选及联用策略开发等关键科学问题。作为核心研究人员开发的新型pan-PI3K抑制剂KTC1101在MedChemExpress公司商业化转化。发表SCI论文18篇，其中第一或通讯作者文章7篇，如Mol Cancer（2篇），Signal Transduct Target Ther，Adv Sci（2篇），Cancer Res，J Exp Clin Cancer Res等，合作文章发表在Cancer Cell等期刊。他引次数588，单篇最高他引次数158，H指数16。

老虎机游戏

1. Xin Peng#, Yingying Wang#, Zixiang Yu#, Shaolu Zhang, Zhenxing Zhong, Yongzhe Wang, Shanshan Liu, Kailin Wang, Christophe Nicot*, Francois X. Claret*, Dexin Kong*. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. Mol Cancer. 2025, 24(1):217. (IF=33.9)

2. Xin Peng#, Xin Huang#, Talal Ben Lulu#, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu, Yongzhe Wang, Kailin Wang, Sho Isoyama, Shingo Dan, Feng Wang, Zhe Zhang*, Moshe Elkabets*, Dexin Kong*. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024, 23(1):54. (IF=41.4)

3. Xin Peng#, Xin Huang#, Shaolu Zhang#, Naixin Zhang, Yingying Wang, Zixiang Yu, Xi Chen, Moshe Elkabets, Francois X. Claret, Feng Wang, Ning Ji*, Yuxu Zhong*, Dexin Kong*. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv Sci. 2024, 11(30):2307747. (IF=14.1)

4. Xin Peng#, Yingying Wang#, Shaolu Zhang#, Zhennan Tao, Yuxiang Dai, Francois X. Claret, Moshe Elkabets, Hou-Wen Lin*, Zhe-Sheng Chen*, Dexin Kong*. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homologous recombination repair. Signal Transduct Target Ther. 2023, 8(1):119. (IF=38.104)

5. Xin Peng, Shaolu Zhang, Yingying Wang, Zhicheng Zhou, Zixiang Yu, Zhenxing Zhong, Liang Zhang, Zhe-Sheng Chen, Francois X. Claret, Moshe Elkabets, Feng Wang, Fan Sun, Ran Wang*, Han Liang*, Hou-Wen Lin*, Dexin Kong*. Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair. Adv Sci. 2023, 10(3):2205529. (IF=17.521)

6. Xin Peng#, Shaolu Zhang#, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang*, Yuxu Zhong*, Zhe-Sheng Chen*, Dexin Kong*. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021, 40(1):374. (IF=11.663)

7. Shaolu Zhang#, Xin Peng#, Xiaofei Li, Hongyan Liu, Baoquan Zhao, Moshe Elkabets, Yao Liu, Wei Wang, Ran Wang, Yuxu Zhong, Dexin Kong*. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021, 12(6):546. (IF=9.685)